In the new technology integration, users with diabetes will be able to transfer recorded data from the Terumo Medisafe With insulin patch pump into the Glooko management platform, allowing for the visualization of insulin dosage, food and activities in graphs.
Tokyo-based Terumo said in a news release that the two companies will begin offering the new diabetes data solution in Europe starting in May 2022. The integration will allow for physicians to view patient data more frequently, whether in-person or remotely through Glooko’s analytics portal.
“We are excited to announce this new patient-focused collaboration with Glooko,” Hikaru Samajima, president of Terumo’s general hospital company, said in the release. “These new solutions will allow people with diabetes to upload their data from home easily without the need to visit the hospital. We believe this is a valuable solution for both patients and healthcare providers, especially under the post-COVID-19 ‘new normal’ lifestyle.”
Both companies are also working on developing a unique method of transferring recorded data from the Medisafe With insulin patch pump to the Glooko mobile app directly via near-field communication (NFC). The launch for that next step is planned for later this year in Europe.
Terumo said that Medisafe With will be the world’s first insulin patch pump with direct NFC connection to the Glooko mobile app, allowing patients to use their smartphones to share diabetes data with their diabetes management team anytime, anywhere.
“Our continued partnership with Terumo means even more access to health data for people with diabetes and their healthcare providers,” Glooko CEO Russ Johannesson said. “We are very pleased to expand our partnership with Terumo by integrating Glooko’s data management and remote patient monitoring platform with the Medisafe With insulin patch pump.
“Having the best connectivity is imperative for delivering world-class care, so we are happy to partner with Terumo to integrate its new insulin patch pump.”
